Atopic DermatitisFeatured PodcastPodcast Highlights

Insights On the Pediatric, Adolescent & Adult AD Patient

By January 11, 2021April 1st, 2022No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

Insights On the Pediatric, Adolescent & Adult AD Patient

Dr. Peter Lio, Dr. Lindsay Finklea & Dr. Adam Friedman

 

You can’t truly understand someone until you walk a mile in their shoes. This is true to so many aspects of daily life, especially when it comes to chronic, relapsing, relentless medical issues. Enter the poster child: Atopic Dermatitis (AD). This exceedingly common chronic inflammatory disease is unavoidable in practice, and to best manage/partner with the millions of patients out there, it is on us to view/appreciate this condition beyond the practitioner lens.

In this 3rd episode of a 5 part podcast series, host Dr. Adam Friedman is joined by Dr. Lindsey Finklea, a practicing dermatologist and parent/caregiver of a child with severe AD, and Dr. Peter Lio, podcast veteran and AD focused Derm extraordinaire, to discuss the issues affecting patient-family/patient-caregiver interactions and offer clinical pearls for effective management strategies to best assist the needs of parents, families and caregivers for patients with the AD.

Listen Now

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.

 

Learning Objectives
Upon completion of this podcast, learners should be able to:
  • Cite the unique clinical implications of atopic dermatitis specific to the pediatric, adolescent and adult AD patient; and
  • Recognize the impact of AD on the patient-family and patient-caregiver dynamic

Disclosures

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Peter Lio, MD – Advisory Board: Altus Labs, Arbonne, Bodewell, Dermavant Sciences, DermTap, Inc., DermVeda, gpower, inc., IntraDerm Pharmaceuticals, Johnson & Johnson Consumer Products Company, Menlo Therapeutics, Micreos Human Health B.V., Modernizing Medicine, National Eczema Association, Realm Therapeutics, Regeneron, Sanofi US Services, Syncere Skin Systems, UCB, Verrica Pharmaceuticals Inc, YobeeCare Inc. Board of Directors: National Eczema Association. Consultant: AbbVie, Amyris, Inc., Burt’s Bees, Dermira, Eli Lilly and Company, Exeltis, Franklin BioScience, Kiniksa Pharmaceuticals, Ltd., L’Oreal USA Inc., LEO Laboratories Ltd (LEO Pharma), Odeza LLC, Theraplex, TopMD, Unilever. Investigator: AbbVie, AOBiome, LLC, La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis, National Eczema Association, Regeneron. Speaker: Galderma USA, La Roche-Posay Laboratorie Pharmaceutique, Pfizer Inc., Pierre Fabre Dermatologie, Regeneron. Stockholder: LearnHealth/LearnSkin, Medable, Modernizing Medicine. Royalties: Theraplex.
Lindsay Finklea, MD – No relevant disclosures.

You May Also Like

Thin Skinned: Topical Steroid Safety and Legal Landmines

| Featured Articles, Latest News, Podcast Highlights, The Latest | No Comments
Just put some salve on it" sounds so innocuous one could follow up with, "what could possibly go wrong?" Never ask that. Yes, our skin is our living breathing barrier…

From Rags to Itches: The Evolution of Topical and Systemic Options for Pruritus

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Life's an itch sometimes….am I right? Pruritus can pick apart the fabric of one's life as both a symptom of a primary skin disease or even as a…
Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array of nonsteroidal options, understanding the underpinnings to both use them for their intended purpose, but even more fun, OOOOOOFFFFFF LLLLLLAAAAABBBBEEEELLLL (clearly a fan of off label), is paramount to patient outcomes. Be not overwhelmed I say, as the bench to bedside badass Dr. Christopher Bunick is here for all your on and off label needs. Take a break from the typical Tuesday with a topical translational deep dive into the tantalizing options as host Dr. Adam Friedman tees off with Dr. Bunick for what is certain to be a “tough” (as the kids say) podcast.

Touching on Tailored Topical for Tons of Tough Treatment Tchallenges

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array…

Leave a Reply